BioMarin

In News

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Mixed Short And Long Term Share Price Performance - simplywall.st

simplywall.st - Feb 14, 2026

BioMarin Announces Closing of Private Offering of Senior Notes - PR Newswire

PR Newswire - Feb 12, 2026

BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace

BioSpace - Feb 12, 2026

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical

BioMarin Pharmaceutical - Dec 19, 2025

BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena

Clinical Trials Arena - Feb 13, 2026

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive

BioPharma Dive - Feb 12, 2026

BridgeBio data for dwarfism drug sets up showdown with BioMarin's Voxzogo - FirstWord Pharma

FirstWord Pharma - Feb 12, 2026

BioMarin finances Amicus acquisition with $850M notes and new loans - Stock Titan

Stock Titan - Feb 12, 2026

Baird maintains BioMarin stock rating amid competitor’s positive trial data - Investing.com

Investing.com - Feb 12, 2026

BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company - TradingView

TradingView - Feb 12, 2026

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Nasdaq

Nasdaq - Feb 11, 2026

Looking To Compete With BioMarin, Ascendis Continues Its Growth Story - Citeline News & Insights

Citeline News & Insights - Feb 12, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment